ישראל - עברית - Ministry of Health

sanofi israel ltd - tuberculin purified protein - תמיסה להזרקה - tuberculin purified protein 5 tu / 0.1 ml - tuberculosis diagnostics - an aid in the detection of infection with mycobacterium tuberculosis.

ישראל - עברית - Ministry of Health

organon pharma israel ltd., israel - betamethasone as dipropionate; betamethasone sodium phosphate - תרחיף להזרקה - betamethasone sodium phosphate 2 mg/ml; betamethasone as dipropionate 5 mg/ml - betamethasone - betamethasone - produces anti-inflammatory, anti rheumatic and anti-allergic action and is indicated for systemic and local therapy of acute and chronic corticosteroid-responsive disorders.

ישראל - עברית - Ministry of Health

neopharm ltd, israel - certolizumab pegol - תמיסה להזרקה - certolizumab pegol 200 mg/ml - certolizumab pegol

ישראל - עברית - Ministry of Health

amgen europe b.v. - adalimumab - תמיסה להזרקה - adalimumab 50 mg / 1 ml - adalimumab

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - buserelin acetate - קנים להשתלה - buserelin acetate 9.9 mg - buserelin - buserelin - treatment of advanced hormone dependent prostatic carcinoma. however not after bilateral orchiectomy ( no further reduction of testosterone level by buserelin to be expected).

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - buserelin acetate 6.6 mg - rods for implant - buserelin - treatment of advanced hormone - dependent prostatic carcinoma.

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - buserelin as acetate 0.1 mg/actuations - solution - buserelin - treatment of advanced hormone dependent prostatic carcinoma. endometriosis. use in ivf. precocious puberty. leyomyoma uteri.

ישראל - עברית - Ministry of Health

intervet ( israel) ltd - buserelin as acetate - תמיסה להזרקה - buserelin as acetate 0.004 mg/ml

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

ישראל - עברית - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*